The mitochondrial and autosomal mutation landscapes of prostate cancer.
暂无分享,去创建一个
Johan Lindberg | Fredrik Wiklund | Jianfeng Xu | Henrik Grönberg | Pernilla Wikström | Daniel Klevebring | Lars Egevad | J. Lindberg | H. Grönberg | I. Mills | Jianfeng Xu | F. Wiklund | Wennuan Liu | P. Wiklund | L. Egevad | D. Klevebring | P. Wikström | Wennuan Liu | Ian G Mills | Peter Wiklund | Mårten Neiman | M. Neiman | Daniel Klevebring
[1] G. Pesole,et al. Mitochondrial genomes gleaned from human whole-exome sequencing , 2012, Nature Methods.
[2] J. Hicks,et al. Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis. , 2002, Cancer research.
[3] Christian Ruiz,et al. Advancing a clinically relevant perspective of the clonal nature of cancer , 2011, Proceedings of the National Academy of Sciences.
[4] C. Sander,et al. Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.
[5] Jennifer R. Rider,et al. The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis , 2012, Cancer Epidemiology, Biomarkers & Prevention.
[6] Eric S. Lander,et al. The genomic complexity of primary human prostate cancer , 2010, Nature.
[7] L. Cavelier,et al. Human brain contains high levels of heteroplasmy in the noncoding regions of mitochondrial DNA. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[8] Irmtraud M. Meyer,et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers , 2012, Nature.
[9] D. Grignon,et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. , 1994, In vivo.
[10] Cesar M. Castro,et al. Ultrasensitive Clinical Enumeration of Rare Cells ex Vivo Using a Micro-Hall Detector , 2012, Science Translational Medicine.
[11] A. Sivachenko,et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer , 2012, Nature Genetics.
[12] S. Varambally,et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. , 2010, Neoplasia.
[13] E. Montgomery,et al. Telomere Length Abnormalities Occur Early in the Initiation of Epithelial Carcinogenesis , 2004, Clinical Cancer Research.
[14] F. Kronenberg,et al. Somatic mutations throughout the entire mitochondrial genome are associated with elevated PSA levels in prostate cancer patients. , 2010, American journal of human genetics.
[15] D. Gisselsson,et al. Telomere dysfunction triggers extensive DNA fragmentation and evolution of complex chromosome abnormalities in human malignant tumors , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[16] M. Beal,et al. High aggregate burden of somatic mtDNA point mutations in aging and Alzheimer's disease brain. , 2002, Human molecular genetics.
[17] M. Stratton,et al. Use of cancer‐specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors , 2010, Genes, chromosomes & cancer.
[18] Hans Garmo,et al. Radical prostatectomy versus watchful waiting in early prostate cancer. , 2005, The New England journal of medicine.
[19] T. Kunkel,et al. DNA precursor asymmetries in mammalian tissue mitochondria and possible contribution to mutagenesis through reduced replication fidelity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[20] D. Samuels,et al. Somatic mitochondrial DNA mutations in cancer escape purifying selection and high pathogenicity mutations lead to the oncocytic phenotype: pathogenicity analysis of reported somatic mtDNA mutations in tumors , 2012, BMC Cancer.
[21] Benjamin J. Raphael,et al. The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2016 .
[22] J. Cuzick,et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. , 2011, The Lancet. Oncology.
[23] M. Goyns. Genes, telomeres and mammalian ageing , 2002, Mechanisms of Ageing and Development.
[24] Stephen J. Salipante,et al. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers , 2011, Proceedings of the National Academy of Sciences.
[25] D. A. Kreutzer,et al. Mutagenicity and repair of oxidative DNA damage: insights from studies using defined lesions. , 1998, Mutation research.
[26] Ronald A. DePinho,et al. The age of cancer , 2000, Nature.
[27] Jun Luo,et al. Copy Number Analysis Indicates Monoclonal Origin of Lethal Metastatic Prostate Cancer , 2009, Nature Medicine.
[28] J. Lindberg,et al. Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins. , 2013, European urology.